Lorenzo Trippa

The effects of releasing early results from ongoing clinical trials.

Authors:

Steffen Ventz Sergio Bacallado Rifaquat Rahman Sara Tolaney Jonathan D Schoenfeld Brian M Alexander Lorenzo Trippa

Nat Commun 2021 02 5;12(1):801. Epub 2021 Feb 5.

Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

View Article and Find Full Text PDF

February 2021

Rationale and design of the Novel Uses of adaptive Designs to Guide provider Engagement in Electronic Health Records (NUDGE-EHR) pragmatic adaptive randomized trial: a trial protocol.

Authors:

Julie C Lauffenburger Thomas Isaac Lorenzo Trippa Punam Keller Ted Robertson Robert J Glynn Thomas D Sequist Dae H Kim Constance P Fontanet Edward W B Castonguay Nancy Haff Renee A Barlev Mufaddal Mahesri Chandrashekar Gopalakrishnan Niteesh K Choudhry

Implement Sci 2021 Jan 7;16(1). Epub 2021 Jan 7.

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA.

View Article and Find Full Text PDF

January 2021

Reply to "Keynote 48: Is it really for everyone?"

Authors:

Jonathan D Schoenfeld Geoffrey Fell Robert I Haddad Lorenzo Trippa

Oral Oncol 2020 Dec 1:105108. Epub 2020 Dec 1.

Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.

View Article and Find Full Text PDF

December 2020

Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center.

Authors:

Katya Losk Rachel A Freedman Alison Laws Olga Kantor Elizabeth A Mittendorf Zhenying Tan-Wasielewski Lorenzo Trippa Nancy U Lin Eric P Winer Tari A King

Breast Cancer Res Treat 2021 Jan 16;185(1):215-227. Epub 2020 Sep 16.

Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA.

View Article and Find Full Text PDF

January 2021

Identifying Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials.

JCO Precis Oncol 2019 15;3. Epub 2019 Nov 15.

Dana-Farber Cancer Institute, Boston, MA.

View Article and Find Full Text PDF

November 2019

Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.

JAMA Oncol 2020 10;6(10):1598-1605

Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article and Find Full Text PDF

October 2020

Optimality of testing procedures for survival data in the nonproportional hazards setting.

Authors:

Andrea Arfè Brian Alexander Lorenzo Trippa

Biometrics 2020 Jun 14. Epub 2020 Jun 14.

Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article and Find Full Text PDF

June 2020

Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant.

Nat Commun 2020 06 12;11(1):2996. Epub 2020 Jun 12.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.

View Article and Find Full Text PDF

June 2020

Shared and Usable Data From Phase 1 Oncology Trials-An Unmet Need.

Authors:

Andrea Arfè Steffen Ventz Lorenzo Trippa

JAMA Oncol 2020 07;6(7):980-981

Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article and Find Full Text PDF

July 2020

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.

J Clin Oncol 2020 07 22;38(21):2380-2389. Epub 2020 May 22.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

View Article and Find Full Text PDF

July 2020

Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide.

Authors:

Rifaquat Rahman Lorenzo Trippa Stephanie Alden Geoffrey Fell Taher Abbasi Yatin Mundkur Neeraj K Singh Anay Talawdekar Zakir Husain Shireen Vali Keith L Ligon Patrick Y Wen Brian M Alexander

Int J Radiat Oncol Biol Phys 2020 Nov 14;108(3):716-724. Epub 2020 May 14.

Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA. Electronic address:

View Article and Find Full Text PDF

November 2020

Keynote 48: Is it really for everyone?

Authors:

Jonathan D Schoenfeld Geoffrey Fell Robert I Haddad Lorenzo Trippa

Oral Oncol 2020 06 4;105:104762. Epub 2020 May 4.

Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.

View Article and Find Full Text PDF

June 2020

A Quantitative Framework for Modeling COVID-19 Risk During Adjuvant Therapy Using Published Randomized Trials of Glioblastoma in the Elderly.

Authors:

Shervin Tabrizi Lorenzo Trippa Daniel Cagney Shyam Tanguturi Steffen Ventz Geoffrey Fell Patrick Y Wen Brian M Alexander Rifaquat Rahman

Neuro Oncol 2020 Apr 27. Epub 2020 Apr 27.

Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

View Article and Find Full Text PDF

April 2020

Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study.

J Clin Oncol 2020 07 24;38(21):2390-2397. Epub 2020 Apr 24.

Dana-Farber Cancer Institute, Boston, MA.

View Article and Find Full Text PDF

July 2020

Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer.

Clin Cancer Res 2020 06 13;26(11):2556-2564. Epub 2020 Mar 13.

Broad Institute of MIT and Harvard, Cambridge, Massachusetts.

View Article and Find Full Text PDF

June 2020

A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer.

Authors:

Romualdo Barroso-Sousa Ian E Krop Lorenzo Trippa Zhenying Tan-Wasielewski Tianyu Li Wafa Osmani Chelsea Andrews Deborah Dillon Edward T Richardson Ricardo G Pastorello Eric P Winer Elizabeth A Mittendorf Jennifer R Bellon Jonathan D Schoenfeld Sara M Tolaney

Clin Breast Cancer 2020 06 30;20(3):238-245. Epub 2020 Jan 30.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA. Electronic address:

View Article and Find Full Text PDF

June 2020

Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis.

Authors:

Laura M Spring Geoffrey Fell Andrea Arfe Chandni Sharma Rachel Greenup Kerry L Reynolds Barbara L Smith Brian Alexander Beverly Moy Steven J Isakoff Giovanni Parmigiani Lorenzo Trippa Aditya Bardia

Clin Cancer Res 2020 06 11;26(12):2838-2848. Epub 2020 Feb 11.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

View Article and Find Full Text PDF

June 2020

A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.

Authors:

José Pablo Leone Dan G Duda Jiani Hu William T Barry Lorenzo Trippa Elizabeth R Gerstner Rakesh K Jain Sally Tan Elizabeth Lawler Eric P Winer Nancy U Lin Sara M Tolaney

Breast Cancer Res Treat 2020 Jan 20;179(1):113-123. Epub 2019 Sep 20.

Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article and Find Full Text PDF

January 2020

Lessons Learned from Deescalation Trials in Favorable Risk HPV-Associated Squamous Cell Head and Neck Cancer-A Perspective on Future Trial Designs.

Authors:

Steffen Ventz Lorenzo Trippa Jonathan D Schoenfeld

Clin Cancer Res 2019 12 16;25(24):7281-7286. Epub 2019 Sep 16.

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article and Find Full Text PDF

December 2019

Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.

Am J Hematol 2019 11 4;94(11):1244-1253. Epub 2019 Oct 4.

Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article and Find Full Text PDF

November 2019

Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications.

Authors:

Rifaquat Rahman Geoffrey Fell Steffen Ventz Andrea Arfé Alyssa M Vanderbeek Lorenzo Trippa Brian M Alexander

Clin Cancer Res 2019 11 25;25(21):6339-6345. Epub 2019 Jul 25.

Department of Radiation Oncology, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article and Find Full Text PDF

November 2019

Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial.

Authors:

Shom Goel Sonia Pernas Zhenying Tan-Wasielewski William T Barry Aditya Bardia Rebecca Rees Chelsea Andrews Rie Kawabori Tahara Lorenzo Trippa Erica L Mayer Eric P Winer Laura M Spring Sara M Tolaney

Clin Breast Cancer 2019 12 30;19(6):399-404. Epub 2019 May 30.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Electronic address:

View Article and Find Full Text PDF

December 2019

Frequentist operating characteristics of Bayesian optimal designs via simulation.

Authors:

Yifan Zhang Lorenzo Trippa Giovanni Parmigiani

Stat Med 2019 09 19;38(21):4026-4039. Epub 2019 Jun 19.

Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article and Find Full Text PDF

September 2019

Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data.

Authors:

Steffen Ventz Albert Lai Timothy F Cloughesy Patrick Y Wen Lorenzo Trippa Brian M Alexander

Clin Cancer Res 2019 08 7;25(16):4993-5001. Epub 2019 Jun 7.

Dana-Farber Program in Regulatory Science, Harvard Medical School, Boston, Massachusetts.

View Article and Find Full Text PDF

August 2019

To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs.

Authors:

Alyssa M Vanderbeek Steffen Ventz Rifaquat Rahman Geoffrey Fell Timothy F Cloughesy Patrick Y Wen Lorenzo Trippa Brian M Alexander

Neuro Oncol 2019 10;21(10):1239-1249

Program in Regulatory Science, Boston, Massachusetts.

View Article and Find Full Text PDF

October 2019

Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia.

J Clin Oncol 2019 06 16;37(16):1403-1411. Epub 2019 Apr 16.

1 Dana-Farber Cancer Institute, Boston, MA.

View Article and Find Full Text PDF

June 2019

Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma.

JCO Precis Oncol 2019 27;3. Epub 2019 Mar 27.

Dana-Farber Cancer Institute, Boston, MA.

View Article and Find Full Text PDF

March 2019

Bayesian adaptive design: the future for regional anesthesia trials?

Authors:

Robert Gotmaker Michael J Barrington John Reynolds Lorenzo Trippa Stephane Heritier

Reg Anesth Pain Med 2019 Mar 2. Epub 2019 Mar 2.

Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia

View Article and Find Full Text PDF

March 2019

Bayesian Adaptive Randomization in Dose-Finding Trials.

Authors:

Steffen Ventz Brian M Alexander Lorenzo Trippa

JAMA Netw Open 2018 12 7;1(8):e186075. Epub 2018 Dec 7.

Dana-Farber Cancer Institute, Department of Biostatistics and Computational Biology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

View Article and Find Full Text PDF

December 2018

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.

Authors:

Romanos Sklavenitis-Pistofidis Marzia Capelletti Chia-Jen Liu Mairead Reidy Oksana Zavidij Daisy Huynh Patrick Henrick Alexandra Savell Kaitlen Reyes Bradley Rivotto Mark Bustoros Adriana Perilla-Glen Lorenzo Trippa Jorge J Castillo Steven P Treon Irene M Ghobrial

Blood 2018 12 26;132(24):2608-2612. Epub 2018 Oct 26.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and.

View Article and Find Full Text PDF

December 2018

Publications by authors named "Lorenzo Trippa"

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors: